About Us

FORGE Life Science brings today's innovation into tomorrow's transformative therapeutics

FORGE today’s life science innovation into tomorrow's transformative therapeutics


FORGE Life Science was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, FORGE antivirals engage the cell’s intrinsic immunity to defend against infection. FORGE’s vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broad-spectrum treatment options. This will transform the practice of medicine because FORGE products will address the infectious disease condition as opposed to targeting a specific virus-type. Imagine being prescribed a safe, broad-spectrum antiviral, without the risk of acquired drug-resistance, based on symptom presentation, and prior to diagnostic confirmation of infecting virus-type. Our highly-innovative products are early-stage, yet we bring tangible solutions to solve real clinical challenges and unmet medical need.


FORGE has four drug discovery programs applying our broad-spectrum antiviral technology in a uniquely apt way to address clinical challenges currently unmet by traditional virus-targeting strategies: (1) a pan-respiratory infections antiviral with demonstrated effectiveness against seasonal, pandemic, and influenza A and B strains resistant to current drugs; (2) a single pill effective against multiple (opportunistic) infections including herpes virus and polyomavirus infections posing serious complications for immunosuppressed patients receiving organ transplants; (3) a brain-penetrant antiviral to treat viral encephalitis; and (4) a liver infections antiviral targeting HBV and HCMV.


Ensuring successful translation of our drug discovery programs to ultimately address patient needs in the clinic, FORGE has a world-class team with proven track record for innovation and commercialization success. We will pursue a focused business plan maximizing non-dilutive funding with broad pharma partnering opportunities in parallel with internal value creation.

Senior Management Team

Prior to FORGE, Lillian was VP of Translational Medicine at Kadmon Corporation. She was responsible for strategy and translation from early discovery through proof of concept in man. Throughout her career she has built from scratch, state-of-the-art technologies, drug discovery & development teams, and businesses at Stanford, Millennium Pharmaceuticals, Purdue Pharma, Aestus Therapeutics, and Kadmon. At Aestus, she applied her own data mining algorithms to identify drug-repositioning assets to acquire and develop in a virtual pharma environment. Aestus' first in-licensed product was successfully advanced from novel mechanism of action & therapeutic hypothesis to completion of phase 2A trial in 5 years and $5 M spend primarily funded by government grants. BS, MIT; PhD, Wisconsin; Post-Doc, Stanford; MBA, Wharton.
Eain joined FORGE in August 2015. Previously he served as Associate Professor in the Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and an Associate Professor of Immunology, Division of Infectious Disease at the Cleveland Clinic. He led and continues to lead at FORGE, a NIH funded research group studying herpesvirus. Dr. Murphy is an expert virologist and principal investigator with special emphasis on viral latency and translational science. He is an associate editor at PLoS Pathogens, and on the Editorial Board of the Journal of Virology.
Tom is Princeton University, James Elkins Professor of Life Sciences. He has received numerous career honors and awards and is a member of the U.S. National Academy of Sciences & Institute of Medicine. Intellectual property from Tom's lab in the fields of molecular biology, gene therapy, vaccines, and virology, has fueled multiple start-ups with successful exits including DNX (IPO), ImClone Systems (IPO), Merlin (acquired by Somatix), Novalon (acquired by Kara Bio), and Cadus (IPO). Tom has served in the past and, also, continues to serve on the Boards of multiple companies and non-profits including Merck & Co., Cell Genesis, CV Therapeutics, the Fox Chase Cancer Center and the Hepatitis B Foundation.
Aaron is a patent attorney with 18 years of IP experience in the pharmaceutical industry. He brings a broad range of experience as in-house counsel for numerous pharma and biotech companies large and small (e.g. Aventis, Hoffmann-La Roche, Organon, Aestus Therapeutics, WellGen), and as outside counsel (at McAulay Nissen Goldberg Kiel & Hand). At Organon, Aaron managed their entire U.S. patent portfolio prior to the acquisition by Schering-Plough. Aaron has a JD from Rutgers and an MS in Biochemistry and Molecular Biology from the University of California, Davis. Currently, he also serves as Assistant Director for Intellectual Property for Mount Sinai Innovation Partners, the technology-licensing arm of the Icahn School of Medicine at Mount Sinai.
Stacy is a medicinal chemist with 30 issued patents spanning tenures at Schering-Plough, Novartis, and Hoffmann-La Roche. At Novartis, Stacy led a multi-disciplinary project team that delivered two compounds to Phase 1 clinical trials within five years. One of those compounds, panobinostat is a histone deacetylase (HDAC) inhibitor developed by Novartis that received marketing approval for treatment of multiple myeloma. Most recently, Stacy was Director of Chemistry, Section Head for Oncology Chemistry and member of the Discovery Chemistry Management Team at Hoffmann-La Roche. Throughout his career he has led in-licensing evaluation and preclinical research teams, consistently delivering strategic collaborations and clinical candidates, while embracing new technologies and developing unique methods to affect drug targets including disrupting protein-protein interactions.


Management Consultants

Scientific Advisory Board

Ileana is a founder of FORGE Life Science and an Associate Professor in the Molecular Biology Department of Princeton University applying proteomics to the study of host-virus interactions. She has received numerous early career awards including the prestigious NIH Avant-Garde Award for Innovative HIV/AIDS Research, the Human Frontier Science Program Award, the ACS Mass Spectrometry Early Career Award, and the American Society for Mass Spectrometry Research Award.
Tage is President and CEO of Aestus Therapeutics. He has a distinguished career in pharmaceutical research, as Vice President of CNS Research at Novartis, Novo Nordisk, and Purdue Pharma, contributing to more than 35 new molecular entities entering clinical development with 4 currently marketed. Tage was a pioneer in the Excitatory Amino Acid Receptor field and has an extensive record in the progression and understanding of this central neuronal pathway. He brings a passion for and skill in interacting with people of different cultures, implementing new organizational models demonstrating record pipeline productivity across every organization he has led. Tage has both a Doctor of Philosophy in Medicinal Chemistry and a Doctor of Science in Neurobiology from the Royal Danish School of Pharmacy in Denmark.
John is the University of Wisconsin, Epigenetics Theme Director of the Wisconsin Institute for Discovery, and Professor of Biomolecular Chemistry. His laboratory focuses on the roles of reversible protein modifications, in particular histone modifications, that are involved in modulating signal transduction, chromatin dynamics and gene expression. John is a key opinion leader in the field of small molecule sirtuin modulators; his lab has both discovered small molecule ligands and significantly advanced the field from early controversies to molecular elucidation of mechanisms of action for synthetic, natural product, and in vivo agonists of multiple family members of sirtuins. John is a Fellow of the AAAS and has received numerous honors including the American Cancer Association Young Investigator and Research Scholar Awards, and the NIH Merit Award.
Peter is the Horace W. Goldsmith Professor and Chair of Microbiology and Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York City. He is a world’s leading expert in RNA and respiratory viruses; his groundbreaking research made it possible to directly manipulate the influenza genome for investigation of viral pathogenicity, and for development and manufacture of novel vaccines. Research in his lab established the first genetic maps for influenza A, B, and C, reconstructed the pathogenicity of the 1918 pandemic virus known as Spanish flu, defined the mechanism of neuraminidase inhibitors, and continues to further our understanding of host-virus interactions providing insights to develop better antivirals and vaccines. Peter is a member of the U.S., German, and Austrian National Academies of Science; among numerous awards, Peter was honored with the Robert Koch Prize in 2006.
Tony has over 30 years of experience in pharmaceuticals, including an extensive tenure at Merck & Co. At Merck Frosst, Canada, Tony led teams that developed Singulair®, Cox-2 inhibitors (Vioxx® and Arcoxia®), prostaglandin DP receptor antagonist (a component of Tredaptive®) and Cat K inhibitors (odanacatib) making the Merck Frosst Laboratories the most productive discovery unit of Merck. Subsequent career highlights at Merck relating to infectious disease include the development of HIV integrase inhibitor Isentress® and development & licensing of therapies to tackle drug-resistant bacterial infections. Tony's most recent responsibility at Merck as head of Vaccine R&D led to commercialization of 4 vaccines; Gardasil®, Zostavax®, Proquad® and Rotateq®. Tony is Chairman of the Board of Directors, MSD Wellcome Trust Hilleman Labs, Board of Trustees, and President, Merck Genome Research Institute.
Pete is Chief Scientific Officer at Zebra Biologics, Inc. He has over 25 years of experience in pharma and biotech including discovering and developing sirtuin modulators as CSO & Sr. Vice President of R&D at Elixir Pharmaceuticals. Elixir’s selisistat (licensed to Siena Biotech) is the only 1st generation synthetic sirtuin modulator still actively pursued in the clinic for the treatment of Huntington's. Pete founded and currently serves on the Board of Directors of Acylin Therapeutics, a biotech start-up focused on histone acetyltransferases. He received his Ph.D. in Pharmacology from Upstate Medical Center in Syracuse and performed his post-doctoral training at Washington University in St. Louis. He has co-authored over 100 manuscripts, reviews and book chapters and is a co-inventor on 12 issued patents.
Alan has over 40 years experience in the pharmaceutical industry (e.g. Pharmacia, USV Pharmaceuticals, DuPont Pharma and Endo Pharmaceuticals). He also worked for IAVI, a non-profit focused on development of vaccines for HIV. Most recently, Alan worked as a consultant for the U.S. government Department of Human and Health Services in the Biological Advanced R&D Administration (BARDA) focusing on Strategic Science and Technology. At BARDA, Alan contributed to several project teams focused on development of new therapeutics and vaccines for treatment and prevention of serious illness due to infection and exposure to chemical, biological and nuclear threats. He currently provides part-time assistance to CARB-X (at BARDA), a public/private initiative aimed at supporting R&D of products for amelioration of the problems associated with bacterial infections which are resistant to available antibiotics. Alan has advanced degrees in both Chemistry and Business.

Business Advisory Board

Dana is a Venture Partner at Hatteras Venture Partners. Previously, he was Executive VP and CSO at Karo Bio AB. As a serial entrepreneur, Dana founded Novalon Pharmaceutical Corp. and negotiated the company’s $107 million merger with Karo Bio AB. As founder of Cadus Pharmaceutical Corp., he negotiated the company’s initial funding round with Mr. Carl Icahn in 1993. Dana has consulted for a number of private equity firms including HBM, Domain Associates, and Medabiotech Ventures.
Raman has more than 40 years of experience in the pharmaceutical industry. He joined Schering-Plough as a financial analyst and served in progressively more responsible finance, marketing and management positions in the US and abroad, including India where he was Managing Director of Fulford. Then he was President of Warrick Pharmaceuticals and President of the Worldwide Generics business of Schering-Plough. Raman now serves as the Chairman of Midland Pharmaceuticals and Global Pharmaceutical Services. He also serves as a director of InnoPharma, as well as several foundations.
Richard Giroux is COO of MeiraGTx and brings 20 years of leadership and experience in capital markets in finance and healthcare to his position. Prior to joining MeiraGTx, Rich was at Sarissa Capital Management LP, an activist healthcare hedge fund. In 2010, Mr. Giroux helped launch and operate Meadowvale Partners, a multi-strategy hedge fund, where he was a founding partner and healthcare portfolio manager. Prior to Meadowvale, he was a partner at Sivik Global Healthcare (formerly Argus Partners), a long/short global equity healthcare fund. From 1996 to 2001, he worked in the equity derivative divisions of Goldman Sachs and Citigroup (formerly Salomon Smith Barney) where he structured, marketed and traded derivative and cash products for domestic and international hedge funds and asset allocators. Mr. Giroux received his BA in Economics from Yale University in 1995.
Brian has advised biotechnology and other life science companies and their investors on corporate, financing and strategic matters for more than 25 years. This work has included venture capital, life science investment and hedge funds, and Medicis Pharmaceutical Corporation (Dynacin®, Restylane®), ImClone Systems, Incorporated, (Erbitux®), Cadus Pharmaceutical Corporation, Merlin Pharmaceutical Corporation, Cephalon, Inc. (Provigil®), SUGEN, Inc. (Sutent®, Crizotinib®), Plexxikon, Inc. (ZELBORAF®) and Kolltan Pharmaceuticals, Inc., where he served on the Board of Directors. He currently serves on the Boards of Microbes, Inc. and Quantum Circuits, Inc. and is a partner at Pusch & Gal, a boutique New York City law firm. A.B, The College of William & Mary in Virginia (Phi Beta Kappa); J.D., University of Virginia.
Steve is President and CEO of Decibel Therapeutics. Prior to Decibel he served as executive vice president, corporate development at Biogen, Inc. At Biogen, Steve created and led the program leadership and management group through six new drug approvals. He also led the business development and M&A group through successful completion of numerous transactions. Prior to Biogen, Steve served as founder and CEO of Infinity Pharmaceuticals, Inc., as the CBO of Millennium Pharmaceuticals, and as founder and EVP of DNX Corporation. Steve is a member of the boards of directors of PMV Pharma, Visterra, Humatics, The Sync Project and Molecular Partners. In the not-for-profit arena, Steve is currently a trustee of the Berklee College of Music and previously served as the vice chairman of the board of trustees of the Hastings Center for Ethics and the Life Sciences. From 1996 to 2001, he served as a Presidential appointee to the U.S. National Bioethics Advisory Commission.
Debbie is Managing Director of at China Renaissance Investment Bank and specializes in cross-border transactions. She has nearly 25 years of experience in the life sciences industry across venture capital, business development, strategy, banking and management consulting. She began her career at McKinsey & Co. and then served as a General Partner at Delphi Ventures and then, Managing Director of Bay City Capital. She next built and co-led Pfizer’s venture capital group in New York City for 5 years. Debbie has stewarded more than 25 companies through venture capital, participated as board member for 8 and stepped in as CEO for 1. Prior to founding Labrador Advisors, she was VP of Strategy at WuxiApptec. BA, Princeton; MD, Harvard.